Antithrombotic prophylaxis in patients with von Willebrand disease undergoing major surgery: When is it necessary?

Journal of Thrombosis and Thrombolysis

Volumn 28, Issue 2, 2009, Pages 215-219

  Franchini, Massimo ^a,b   Targher, Giovanni ^c   Montagnana, Martina ^c   Lippi, Giuseppe ^c  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b OSPEDALE POLICLINICO   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

Concentrates; Low molecular weight heparin; Surgery; Thromboprophylaxis; Venousthromboembolism; von Willebrand disease

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; LOW MOLECULAR WEIGHT HEPARIN; VON WILLEBRAND FACTOR;

AGE; ARTICLE; BLEEDING TIME; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; LUNG EMBOLISM; MAJOR SURGERY; OBESITY; ORTHOPEDIC SURGERY; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK BENEFIT ANALYSIS; RISK FACTOR; SUPERFICIAL THROMBOPHLEBITIS; SURGICAL RISK; SURGICAL TECHNIQUE; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE;

FIBRINOLYTIC AGENTS; HUMANS; POSTOPERATIVE COMPLICATIONS; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 67849110064     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-008-0253-7     Document Type: Article

References (13)

1. Rodeghiero F, Castaman G, Dini E (1987) Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 69:454-459
2. Castaman G, Federici AB, Rodeghiero F, Mannucci PM (2003) von Willebrand's disease in the year 2003: Towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 88:94-108
3. Franchini M, Lippi G (2007) The role of von Willebrand factor in hemorrhagic and thrombotic disorders. Crit Rev Clin Lab Sci 44:115-149. doi: 10.1080/10408360600966753
4. Mannucci PM (2004) Treatment of von Willebrand's disease. N Engl J Med 351:683-694. doi: 10.1056/NEJMra040403
5. Rodeghiero F, Castaman G (2005) Treatment of von Willebrand disease. Semin Hematol 42:29-35. doi: 10.1053/j.seminhematol.2004.10.001
6. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345:152-155. doi: 10.1016/ S0140-6736(95)90166-3
7. Makris M, Colvin B, Gupta V, Shields ML, Smith MP (2002) Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost 88:387-388
8. Mannucci PM (2002) Venous thromboembolism in von Willebrand disease. Thromb Haemost 88:378-379
9. Mannucci PM, Chediak J, Hanna W, Byrnes J, Marlies L, Ewenstein BM, Alphanate Study Group (2002) Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: A prospective, multicenter study. Blood 99:450-456. doi: 10.1182/ blood.V99.2.450
10. Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM, The Haemate P Surgical Study Group (2007) von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: A prospective multicenter trial in elective surgery. J Thromb Haemost 5:1420-1430. doi: 10.1111/j.1538-7836.2007.02588.x
11. Kyrle PA, Minar E, Hirschl M et al (2000) High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343:457-462. doi: 10.1056/NEJM200008173430702
12. Wells PS, Langlois NJ, Webster MA, Jaffey J, Anderson JA (2005) Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada - is it necessary to define a new upper reference range for factor VIII? Thromb Haemost 93:842-846
13. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F (1992) Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: A cross-over randomized trial. Blood 79:3130-3137